Translational Research in Stem Cell Treatment of Neuromuscular Diseases

Table 2

Table summarizing the clinical trials on the treatment of ALS with stem cells.

Phase	Stem cell	Followup	Results	Reference
—	BMCs		No adverse effects observed but final result not mentioned	[14]
—	BMCs	3 years	A significant slowing down of the linear decline of the forced vital capacity	[2]
—	BMCs	4 years	No adverse effects observed but final result not mentioned	[15]
—	G-CSF mobilized HSCs	6 months	No adverse effects observed but final result not mentioned	[19]
II	BM derived HSCs	1 year	9 patients showed clinical improvement confirmed by electroneuromyography. One patient was stabilized. No benefit observed in three patients	[78]
—	G-CSF mobilized HSCs	1 year	No adverse effects observed. Increased survival	[79]
I/II	BMCs	6 months	No adverse effects observed, disease symptoms stabilized	[80]
I-II	BMCs	6 months	Minor side effects were transient fever, headache. No major adverse effects were observed. Clinical improvement observed	[81]
—	G-CSF mobilized HSCs	—	No clinical benefit	[18]
—	G-CSF mobilized HSCs	—	No adverse effects but final result not mentioned	[20]
I	BMCs	1 year	No adverse effects observed but final result not mentioned	[16]
I	BMCs	9 years	No clinical benefit in long-term followup but the symptoms stabilized	[17]